Recent Finacing
Recent Raise
BridGene Biosciences develops small-molecule drugs for traditionally hard-to-drug targets using its IMTAC chemoproteomic platform.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at BridGene Biosciences.
